$NTHISep 14, 2026, 9:07 AM ETAI processed
NTHI insiders buy as NeOnc pushes NEO100 toward FDA meeting after Phase 2a readout
AI Summary
NeOnc's CEO bought 37,000 shares at $3.6654 (~$136k) just after the company announced a $15M registered direct at $4.20, signaling insider conviction while the financing offers potential dilution. The company reported Phase 2a topline for intranasal NEO100 in recurrent IDH1-mutant high‑grade glioma (24 patients, open‑label, single‑arm): 48.9% six‑month PFS versus a 20% prespecified benchmark and median OS of 26.09 months, and says it will request a Type B meeting with the FDA to discuss a potential registrational path. Timing: The press release does not indicate dilution today. Earliest dilution: date unknown.
Positives
- CEO purchased 37,000 shares at $3.6654 (~$136,000) after the company announced a $15M registered direct at $4.20
- Phase 2a topline: 48.9% six‑month PFS vs prespecified 20% benchmark and median OS 26.09 months
- Company plans to request a Type B meeting with FDA to discuss potential registrational pathway
Negatives
- Phase 2a was small (24 patients), open‑label and single‑arm — results are preliminary
- Registered direct offering ($15M at $4.20) presents near‑term dilution risk
- FDA discussions and a Type B meeting do not guarantee a registrational path or approval
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: date unknown
Dilution status
delayed
Dilution timing
Dilution status: Delayed